We are live on ! Find out more
ASBP

Aspire Biopharma
ASBP

28 hedge funds and large institutions have $900K invested in Aspire Biopharma in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

39% more capital invested

Capital invested by funds: $646K → $900K (+$254K)

22% more funds holding

Funds holding: 23 → 28 (+5)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% less ownership

Funds ownership: 0.01% → 0% (-0%)

Holders
28
Holders Change
+5
Holders Change %
+21.74%
% of All Funds
0.34%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
7
Increased
6
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$523K
2
Jane Street
Jane Street
New York
+$137K
3
XT
XTX Topco
Cayman Islands
+$49.5K
4
VF
Virtu Financial
New York
+$22.8K
5
Verition Fund Management
Verition Fund Management
Connecticut
+$20.3K

Top Sellers

Rank Fund Capital Flow
1
PA
Procyon Advisors
Connecticut
-$50K
2
TRCT
Tower Research Capital (TRC)
New York
-$4.5K
3
Focus Partners Wealth
Focus Partners Wealth
Massachusetts
-$2.58K
4
SWA
SOA Wealth Advisors
New York
-$602
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$500
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$332K +$523K +2,090 +34,833%
CA
2
Crewe Advisors
Utah
$107K – – –
Jane Street
3
Jane Street
New York
$90.8K +$137K +549 +2,288%
Vanguard Group
4
Vanguard Group
Pennsylvania
$56.6K – – –
OAS
5
Optivise Advisory Services
Tennessee
$47.1K +$19.5K +78 +35%
XT
6
XTX Topco
Cayman Islands
$35K +$49.5K +198 +861%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$32.7K -$500 -2 -1%
PA
8
Procyon Advisors
Connecticut
$30.7K -$50K -200 -51%
AC
9
Antara Capital
New York
$26.8K – – –
RA
10
Resolute Advisors
California
$20.6K +$15.3K +61 +88%
TSW
11
Three Seasons Wealth
Utah
$16.5K +$10.3K +41 +65%
VF
12
Virtu Financial
New York
$14K +$22.8K +91 New
VAS
13
VR Advisory Services
Cayman Islands
$12.8K – – –
Verition Fund Management
14
Verition Fund Management
Connecticut
$12.8K +$20.3K +81 New
EWA
15
EP Wealth Advisors
California
$8.27K +$13K +52 New
PSAMP
16
P. Schoenfeld Asset Management (PSAM)
New York
$7.72K – – –
AW
17
Avion Wealth
Texas
$7K – – –
SRL
18
Scientech Research LLC
New Jersey
$6.81K +$10.8K +43 New
PC
19
Periscope Capital
Ontario, Canada
$6.59K – – –
CIBC Private Wealth Group
20
CIBC Private Wealth Group
Georgia
$6.48K – – –
VWM
21
Valley Wealth Managers
New Jersey
$5.28K – – –
PTP
22
Platform Technology Partners
New York
$4.96K – – –
CA
23
Crossingbridge Advisors
New York
$3.21K – – –
SG
24
StoneX Group
New York
$1.94K +$3K +12 New
Point72 Asset Management
25
Point72 Asset Management
Connecticut
$1.88K +$3K +12 New
1
2

ASBP Hedge Fund Activity: Q4 2025 in Review

28 of the 8,226 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q4 2025, worth a combined $900K — up 39% from $646K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ASBP positions and 2 closed out — a net gain of 5 holders — while 6 added to existing stakes and 3 trimmed.

The largest buyer was UBS Group, adding an estimated $523K. The largest seller was Procyon Advisors, cutting an estimated $50K.

  • 28 institutional investors held Aspire Biopharma (ASBP) as of Q4 2025, up from 23 in Q3 2025.
  • Funds reported $900K of Aspire Biopharma stock for Q4 2025, up 39% quarter-over-quarter.
  • 7 funds opened new Aspire Biopharma positions in Q4 2025 and 2 closed out, a net change of +5 holders.
  • The largest Aspire Biopharma buyer in Q4 2025 was UBS Group, an estimated $523K added.
  • The largest Aspire Biopharma seller in Q4 2025 was Procyon Advisors, an estimated $50K sold.

Based on aggregated 13F filings for Q4 2025.